Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | 阶段
第二阶段
|
Date Added 2017-12-07 |
地点
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
标签
MSS/ MMRp
|
| NCT ID NCT03657641 |
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2018-09-05 |
地点
California, United States
Florida, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSS/ MMRp
|
| NCT ID NCT03296137 |
TitleAdoptive Cell Therapy Across Cancer Diagnoses | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2017-09-28 |
地点
丹麦
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT03599765 |
Title治疗寡转移性实体瘤患者的全身疗法与局部巩固疗法 | 阶段
第二阶段
|
Date Added 2018-07-26 |
地点
Arizona, United States
Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03568058 |
TitlePersonalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | 阶段
第 1 阶段
|
Date Added 2018-06-26 |
地点
California, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab, personalized vaccine, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT04003792 |
Title肝动脉灌注奥沙利铂联合全身 FOLFIRI 化疗和贝伐珠单抗治疗纯肝结直肠癌肝转移瘤 (CRLM)患者：最初无法手术的纯肝结直肠癌肝转移瘤患者转为完全切除术。 | 阶段
第二阶段
|
Date Added 2019-07-01 |
地点
以色列
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, FOLFIRI Protocol, oxaliplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02988960 |
TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2016-12-12 |
地点
California, United States
Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States 澳大利亚 加拿大 法国 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ABBV-181, ABBV-927, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT04426669 |
Title利用 CRISPR 基因工程抑制编码细胞内免疫检查点 CISH 基因的肿瘤浸润淋巴细胞治疗转移性胃肠癌的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2020-06-11 |
地点
Minnesota, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04062721 |
TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases | 阶段
第 1 阶段
|
Date Added 2019-08-20 |
地点
法国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Chemotherapy, In situ immunotherapy |
标签
MSS/ MMRp
|
| NCT ID NCT04895709 |
Title一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究 | 阶段
Phase 1, Phase 2
|
Date Added 2021-05-20 |
地点
California, United States
Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 德国 以色列 意大利 日本 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BMS-936558-01, BMS-986340 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
